

IASLC 2022 World Conference on Lung Cancer  
Industry Sponsored Symposium



# FUTURE DIRECTIONS IN NSCLC: TAILORING TREATMENT OPTIONS

**Saturday 6 August 2022, 12:00–13:00 PM CEST**

Hall C2, Messe Wien Exhibition & Congress Center, Vienna, Austria

Available on-demand until Wednesday 9 November 2022

**12:00–12:05 PM CEST**

## Welcome and Introduction

David Planchard, MD, PhD

**12:05–12:15 PM CEST**

## The Changing Landscape in NSCLC

David Planchard, MD, PhD

**12:15–12:30 PM CEST**

## New Approaches for Overcoming CPI Resistance in NSCLC

David Carbone, MD, PhD

**12:30–12:50 PM CEST**

## Targeting KRAS: Novel Opportunities for KRAS<sup>G12C</sup>-Driven NSCLC

Marina Garassino, MD

**12:50–13:00 PM CEST**

## Summary and Q&A

David Planchard, MD, PhD

David Carbone, MD, PhD

Marina Garassino, MD



### DAVID PLANCHARD, MD, PhD

Gustave Roussy  
Villejuif, France



### DAVID CARBONE, MD, PhD

The Ohio State University  
Comprehensive Cancer Center,  
James Thoracic Oncology Center  
Columbus, Ohio



### MARINA GARASSINO, MD

University of Chicago  
Chicago, Illinois

**MIRATI**  
THERAPEUTICS

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

This Industry Sponsored Symposium is organized and sponsored by Mirati Therapeutics, Inc.  
©2022 Mirati Therapeutics, Inc.